Table of Contents
- What is Obefazimod?
- What Condition Does Obefazimod Target?
- How Does Obefazimod Work?
- Current Clinical Trial
- Dosage and Administration
- How Efficacy is Measured
- Safety Monitoring
What is Obefazimod?
Obefazimod is a new drug currently being studied for the treatment of moderately to severely active Crohn’s disease. It is undergoing clinical trials to evaluate its effectiveness and safety in patients who have not responded well to conventional therapies or more advanced treatments.[1]
What Condition Does Obefazimod Target?
Obefazimod is specifically being tested for moderately to severely active Crohn’s disease. Crohn’s disease is a type of inflammatory bowel disease that causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The term “moderately to severely active” indicates that the symptoms are significant and impacting the patient’s quality of life.[1]
How Does Obefazimod Work?
While the exact mechanism of action is not detailed in the provided information, Obefazimod is being studied as both an induction and maintenance therapy. This means it’s being tested for its ability to both bring about initial improvement in Crohn’s disease symptoms (induction) and maintain that improvement over time (maintenance).[1]
Current Clinical Trial
Obefazimod is currently being studied in a Phase 2b clinical trial. This trial is designed to evaluate the drug’s efficacy, safety, how it’s processed in the body (pharmacokinetics), and its effects on the body (pharmacodynamics). The study has three main phases:[1]
- 12-Week Induction Phase: This initial phase aims to see if Obefazimod can induce improvement in Crohn’s disease symptoms.
- 40-Week Maintenance Phase: This longer phase evaluates if Obefazimod can maintain the improvements achieved in the induction phase.
- 48-Week Extension Phase: This phase primarily focuses on evaluating the long-term safety and tolerability of Obefazimod.
The study is described as multicenter (conducted at multiple medical centers), double-blind (neither patients nor researchers know who’s receiving the actual drug or placebo), and placebo-controlled (some patients receive a placebo for comparison).[1]
Dosage and Administration
In the clinical trial, Obefazimod is being tested at three different dosage levels:[1]
- 50 mg once daily
- 25 mg once daily
- 12.5 mg once daily
The drug is administered once daily in a fed condition, which means it should be taken with food. It’s recommended to take it at the same time each morning.[1]
How Efficacy is Measured
The effectiveness of Obefazimod is being evaluated using several measures:[1]
- Crohn’s Disease Activity Index (CDAI): This is a tool used to measure the severity of Crohn’s disease. The study looks at changes in CDAI scores at weeks 12 and 52.
- Simple Endoscopic Score for Crohn’s disease (SES-CD): This measures the severity of intestinal inflammation as seen during an endoscopy. Changes in this score are evaluated at week 52.
- Endoscopic response: This refers to significant improvement in the appearance of the intestines during an endoscopy.
- Clinical remission: This is when symptoms are significantly reduced or absent.
- Clinical response: This refers to a meaningful improvement in symptoms.
These measures are assessed at various time points throughout the study to determine how well Obefazimod is working.[1]
Safety Monitoring
The safety of Obefazimod is being closely monitored throughout the study, particularly during the Extension Phase. This includes:[1]
- Tracking all adverse events (side effects) that occur during treatment
- Monitoring blood tests for changes in various health indicators, including:
- Blood cell counts
- Liver function tests
- Kidney function tests
- Cholesterol levels
- Markers of inflammation and heart health
This comprehensive monitoring helps ensure the safety of study participants and provides valuable information about the potential side effects of Obefazimod.[1]
